Vicore Pharma to Participate in the Jefferies Global Healthcare Conference

Vicore Pharma (VCRE) will participate in the Jefferies Global Healthcare Conference in London on November 19, 2026.

Rhea-AI Summary

Vicore Pharma (VCRE) will participate in the Jefferies Global Healthcare Conference in London on November 19, 2026.

The format includes a fireside chat and one-on-one meetings, with a scheduled time of 12:00–12:25 PM GMT. Participants include CEO Ahmed Mousa, CFO Hans Jeppsson, Chief Business Officer Jimmie Hofman, Chief Medical Officer Bernt van den Blink and Chief Scientific Officer Rob Slack.

Key Terms

angiotensin II type 2 receptor agonist, orphan drug designation, fast track designation, idiopathic pulmonary fibrosis

4 terms

angiotensin II type 2 receptor agonist medical

"oral small-molecule angiotensin II type 2 receptor agonist"

A molecule that binds to and activates the angiotensin II type 2 receptor (AT2R), a specific protein on cell surfaces that triggers biological pathways involved in blood vessel tone, inflammation, tissue repair and organ protection. Think of the receptor as a lock and the agonist as a key that turns it on to produce a cellular response. These drugs matter to investors because they represent a category of therapeutic candidates with potential clinical and commercial impact in cardiovascular, renal and fibrotic conditions.

orphan drug designation regulatory

"received Orphan Drug and Fast Track designations"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

fast track designation regulatory

"received Orphan Drug and Fast Track designations"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

idiopathic pulmonary fibrosis medical

"Phase 2b ASPIRE trial in IPF"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / November 10, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the Jefferies Global Healthcare Conference.

Location: London, UK

Format: Fireside chat and 1×1 meetings

Date and time: Thursday, November 19, 2026, 12:00-12:25 PM GMT

Participants:

• Ahmed Mousa, Chief Executive Officer
• Hans Jeppsson, Chief Financial Officer
• Jimmie Hofman, Chief Business Officer
• Bernt van den Blink, Chief Medical Officer
• Rob Slack, Chief Scientific Officer

Webcast: Link

For further information, please contact:
Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Pharma to Participate in the Jefferies Global Healthcare Conference

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire